27 December 2002
An analysis of prognostic factors and the five-year survival rate in childhood acute lymphoblastic leukemia.
Mehran Karimi, Hooman Yarmohammadi, Mohammad R. SabriMed Sci Monit 2002; 8(12): CR792-796 :: ID: 4810
Abstract
BACKGROUND: Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in childhood. With newer drug protocols the five-year survival rate is now close to 80%. Various factors have been reported to be important for prognosis and should be considered when planning MATERIAL/METHODS: In a cross-sectional study, prognostic variables and the five-year survival rate were analyzed. Data regarding demographic characteristics, family and personal history, manifestations at the time of presentation, therapeutic regimens and outcome were collected from the records of 76 ALL patients in treatment five years prior to the study. Two pathologists performed the staging using the morphology method (L1, L2 and L3). RESULTS: Fifty-five subjects (72.5%) survived until the end of the study. One subject succumbed to the rapid fatal course of the disease and 20 others passed away due to relapses or infection during follow-up. CONCLUSIONS: Among all variables a worse prognosis was associated (p<0.05) with WBC counts greater than 50,000/ml at presentation, relapse in the CNS, and relapse in the bone marrow. When Anthracycline was included in the therapeutic regimen, the effect of chemotherapy was more favorable compared to regimens without Anthracycline (p<0.05). Other variables previously reported to have prognostic value, especially age and sex, were not significant in our study (p>0.05). Other factors which might account for a poorer prognosis included the preponderance of L-2 morphology, difficult access to medical care, decreased compliance of families due to exhausted economic and psychological reserves, and inadequate knowledge about the disease course and treatment.
Keywords: Iran - epidemiology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952